INDP is trading 6.5% down at $3.53 in pre-market, extending the sharp volatility seen over the past two weeks despite a lack of new company-specific news.
- No new company-specific headlines, filings, analyst calls, or regulatory updates have been reported since June 22, 2026.
- The move appears consistent with typical micro-cap biotech swings and a slightly weaker broader market tone in U.S. equity futures.